Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/9867

Title: Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Authors: Piessevaux, H.
De Roock, W.
Prenen, H.
Schlichting, M.
Van Cutsem, E.
Tejpar, S.
Issue Date: 2009
Citation: ANNALS OF ONCOLOGY, 20(8). p. 1375-1382
Abstract: Patients and methods: Of the 329 patients, 289 had a measurement both at baseline and week 6. Tumor shrinkage was expressed as a relative decrease compared with baseline and categorized according to a previously reported cut-off value (similar to 10%) or used as a continuous variable. Results: Median time to progression (TTP) was 6.1 [95% confidence interval (CI) 5.1-7.2] versus 1.5 months (95% CI 1.4-1.7) in patients with [99 patients (34.3%)] or without [190 patients (65.7%)] tumor shrinkage, respectively, at week 6 [hazard ratio (HR) 0.23 (95% CI 0.17-0.32)]. The median overall survival (OS) was 13.7 (CI NA) versus 6.9 months (95% CI 6.1-7.7) [HR 0.21 (95% CI 0.14-0.32)], respectively. In a multivariate model, early tumor decrease outperformed skin toxicity as a predictor of long-term outcome. Conclusions: Tumor shrinkage at 6 weeks is a strong predictor of TTP and OS in cmCRC patients treated with cetuximab with or without irinotecan. This suggests early tumor shrinkage is the hallmark of efficacy of cetuximab and reliably identifies the subpopulation that is sensitive to the drug. Early tumor shrinkage can be used as a marker of efficacy in clinical practice, as such or in combination.
Notes: [De Roock, W.; Prenen, H.; Van Cutsem, E.; Tejpar, S.] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Piessevaux, H.] Univ Catholique Louvain, Serv Gastroenterol, Clin Univ St Luc, B-1200 Brussels, Belgium. [Buyse, M.] Int Inst Drug Dev, Louvain, Belgium. [Buyse, M.] Univ Hasselt, Ctr Stat, Diepenbeek, Belgium. [Schlichting, M.] Merck KGaA, Darmstadt, Germany.
URI: http://hdl.handle.net/1942/9867
DOI: 10.1093/annonc/mdp011
ISI #: 000268806700011
ISSN: 0923-7534
Category: A1
Type: Journal Contribution
Validation: ecoom, 2010
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.